Drug intelligence / Profile preview

Veronate

Development stage: Phase 3
Lead developer: Bristol Myers Squibb
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

Veronate is a donor-selected staphylococcal human immune globulin intravenous (IGIV) developed by Inhibitex, Inc. under license from BioResearch, with Bristol-Myers Squibb serving as a lead sponsor for its clinical trials. It was investigated as an antibody-based immunotherapy for the prevention of nosocomial staphylococcal sepsis, as well as Staphylococcus epidermidis, Staphylococcus aureus, and Candida infections in premature and very-low-birth-weight infants.

Brand names: Veronate
Other names: Staphylococcal immunoglobulin (human)Donor-selected Staphylococcal human immune globulin

Beyond the preview

Go deeper on Veronate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Veronate.

Explore the full profile